Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acoziborole - Drugs for Neglected Diseases Initiative Foundation

Drug Profile

Acoziborole - Drugs for Neglected Diseases Initiative Foundation

Alternative Names: AN-5568; Oxaborole SCYX-7158; SCYX-7158

Latest Information Update: 23 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anacor Pharmaceuticals; SCYNEXIS
  • Developer Drugs for Neglected Diseases Initiative Foundation
  • Class Antiprotozoals; Benzamides; Organic boron compounds; Small molecules
  • Mechanism of Action Protein biosynthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III African trypanosomiasis

Most Recent Events

  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 08 Sep 2015 Anacor Pharmaceuticals and the Drugs for Neglected Diseases Initiative Foundation completes a phase I trial in African trypanosomiasis (In volunteers) in France
  • 08 Sep 2015 Drugs for Neglected Diseases Initiative Foundation and partners plans a pivotal phase IIb/III trial for African trypanosomiasis in Congo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top